On January 26, 2026, Geli Pharmaceutical Co., Ltd. (Hong Kong Stock Exchange Code: 1672, referred to as "Geli") announced today that its American 3-week Phase II Study (NCT07321678) of oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in the treatment of type 2 diabetes had completed the administration of the first batch of subjects. The top line data for this Phase 1 study is expected to be obtained in the third quarter of 2026.
Geli has recently completed a 13 week Phase I study evaluating ASC30 treatment for obesity (NCT07002905). The study was conducted at multiple centers in the United States, with a total of 125 obese subjects or overweight subjects with at least one weight related comorbidity enrolled. At the primary endpoint of week 13, daily administration of 20mg, 40mg, and 60mg ASC30 tablets achieved placebo adjusted mean weight loss of 5.4%, 7.0%, and 7.7%, respectively.The weight loss was statistically significant and clinically significant, with daily dose dependence.
No weight loss plateau period was observed. The vomiting incidence of ASC30 titrated weekly until the daily standard dose is approximately half of the vomiting incidence observed in the published weekly full dose orforglipron. The gastrointestinal tolerance of ASC30, which is titrated weekly, is comparable to the published results of orforglipron titrated every four weeks in the Sichuan ATTAIN-1 study. In the phase I study of ASC30 for the treatment of obesity or overweight, the overall discontinuation rate due to adverse events was 4.8%
Eli Lilly GLP1R/GIPR dual agonist initiates phase III clinical trials of depression
On January 26, 2026, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed that Eli Lilly had registered a phase II clinical study of Breipatide injection in adult participants with depression. This is a Phase II, multicenter, randomized, double-blind, parallel group design study (RENEW-MDD-1) aimed at evaluating the efficacy and safety of Breipatide as an adjuvant therapy in delaying disease recurrence time compared to placebo in adult depression participants. The experiment is planned to recruit from 200 institutions worldwide, with 90 people recruited domestically and 1000 people recruited internationally. Brenipatide is a GLP1R/GIPR dual agonist and also the second GLP-1/GIP dual target new drug from Eli Lilly, following Telopotide. Tilpotide sold for 24.8 billion US dollars in the first three months of 2025, with a growth rate of 125%.
Losing 22.5% weight in 48 weeks! Roche GLP-1R/GIPR agonist weight loss phase I1 study achieves positive results
On January 27, 2026, Roche announced positive results in the weight loss phase I CT388-103 study of CT-388 (RO7795068).
CT-388 is a peptide GLP-1R/GIPR agonist developed by Carmot Therapeutics. In December 2023, Roche acquired Carmot Therapeutics for $3.1 billion, acquiring multiple intestinal insulinotropic drugs under the company's umbrella.
The research results showed that CT-388 exhibited a significant dose-response relationship. From the perspective of treatment efficacy (all subjects persisted in treatment), at week 48, obese or overweight subjects receiving CT-388 (low, medium, and high doses, up to 24mg, once a week, subcutaneous injection) treatment had a maximum weight loss of 22.5% (adjusted for placebo group, p<0.001), with statistical and clinical significance, and had not yet reached the weight loss plateau at week 48.
Lilly Amlin receptor agonist initiates Phase II clinical treatment for obstructive sleep apnea
On January 27, 2026, the US Clinical Trial Registry website announced that Eli Lilly has launched the first Phase I clinical trial of Eloralintide (LY3841136) (NCT07369011). The study aims to evaluate the efficacy and safety of Eloralintide in patients with moderate to severe obstructive sleep apnea (OSA) who are obese or overweight. YDAO is a main experimental protocol intended to support two independent studies (YSA1 and YSA2). Among them, YSA1 study enrolled subjects who were unable or unwilling to receive positive airway pressure ventilation treatment, while YSA2 study enrolled subjects who had received the treatment for at least 3 months at the time of screening and planned to continue receiving treatment during the study period.
The total participation period of the study was about 76 weeks, and the main endpoints were the percentage change in body weight and the change in apnea hypopnea index (AHI) from baseline at week 64. Eloralintide is an amyloid receptor (AMYR) agonist developed by Eli Lilly, which may reduce calorie intake by affecting appetite or increasing satiety.
On December 15, 2025, Eli Lilly launched the first phase clinical trial of Eloralintide (ENLIGHT EN-2). This phase of the study is to evaluate the effectiveness and safety of Elaralinitide (four doses, subcutaneous injection) compared with placebo in treating obese or overweight subjects with type 2 diabetes. The primary endpoint of the study was the percentage change in body weight from baseline at week 64.